A pilot prospective comparison of [Ga-68]Ga-P16-093 and [Ga-68]Ga-PSMA-617 in the same group of prostate cancer patients

Guochang Wang,Jie Zang,Haiyan Hong,Qingxing Liu,Yuanyuan Jiang,Zhaohui Zhu,Lin Zhu,Hank Kung

2021-01-01

Abstract:1329 Objectives: This pilot study was prospectively designed to evaluate the early dynamic distribution of [68Ga]Ga-P16-093, a novel radiopharmaceutical targeting prostate-specific membrane antigen, which was compared with [68Ga]Ga-PSMA-617 in the same group of prostate cancer patients.\n Methods: Fourteen patients with prostate cancer (4 patients with primary prostate cancer and 10 patients with relapsed metastatic prostate cancer) were enrolled with ethical committee approval and written informed consent. In two consecutive days each patient underwent a 60-min dynamic PET/CT scan after intravenous administration of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-617, respectively, (injection dose 148-185 MBq per each). Following a low-dose CT scan, serial dynamic PET scans were performed from pelvis to head at 9 time points (30 sec/bed at 4, 7, 10, 13, 16 min, 1 min/bed at 20, 30, 45 min, and 2 min/bed at 60 min). Standardized uptake values (SUV) were measured for each lesion and organ for self-comparison.\n Results: Compared to [68Ga]Ga-PSMA-617, [68Ga]Ga-P16-093 showed a significantly higher tumor uptake and less blood pool retention. The difference is noticable from 4 min and continuously increasing during 60 min. At 60 min, the SUVmax of prostate cancer and metastases were 20.02±14.79 for [68Ga]Ga-P16-093 and 13.66±10.77 for [68Ga]Ga-PSMA-617 (P=0.000), whereas the SUVmean of blood pool were 1.35±0.25 for [68Ga]Ga-P16-093 and 2.53±0.53 for [68Ga]Ga-PSMA-617 (P=0.000). Significantly higher [68Ga]Ga-P16-093 uptakes were also observed in the parotid glands (SUVmean 3.56±0.71 vs 2.85±0.75 at 4 min, P=0.010), liver (SUVmean 5.38±0.99 vs 4.14±0.70 at 4 min, P=0.000), and spleen (SUVmean 5.45±1.19 vs 4.09±0.88 at 4 min, P=0.000). Accumulation of [68Ga]Ga-P16-093 in the bladder appeared to be lower (SUVmean 25.18±15.33 vs 41.91±35.64 at 60 min, P=0.089) and there was no significant difference in kidney uptake (SUVmean 19.18±4.36 vs 31.66±28.67 at 10 min, P=0.113).\n Conclusions: [68Ga]Ga-P16-093 shows advantages over [68Ga]Ga-PSMA-617 with higher tumor uptakes and less blood pool retention in prostate cancer patients. This finding warrants further investigation in a larger number of patients. Figure legend: Serial PET images (A and B) and the SUV changes (C) demonstrated higher tumor uptake and less blood pool retention of [68Ga]Ga-P16-093 (A) over [68Ga]Ga-PSMA-617 (B) in prostate cancer patients. There was an increased the diagnostic confidence in evaluation of mediastinal lymphnode metastasis in the prostate cancer patient (indicated by green arrows). Figure C comparison of time-activity curves of these two tracers in tumor, blood, bladder, kidney, parotid gland, liver, and spleen.